SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Sumatriptan 100mg film-coated Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film coated tablet contains 100mg sumatriptan (as the succinate).
Excipient: each tablet contains 360.04 mg of lactose, as the anhydrous and monohydrate forms
For a full list of excipients see section 6.1.

3 PHARMACEUTICAL FORM

Film-coated Tablet
Capsule shaped white film coated tablets embossed ‘RDY’ on one face and ‘293’ on the other.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Sumatriptan is indicated for the acute relief of migraine attacks, with or without aura.

4.2 Posology and method of administration

Adults

Sumatriptan is indicated for the acute intermittent treatment of migraine. It should not be used prophylactically.

It is advisable that sumatriptan be given as early as possible after the onset migraine attack but it is equally effective at whatever stage of the attack it is administered.

The recommended dose of oral sumatriptan is a single 50 mg tablet. Some patients may require 100 mg. If the patient has responded to the first dose but the symptoms recur a second dose may be given in the next 24 hours provided that there is a minimum interval of two hours between the two doses and no more than 300 mg is taken in any 24 hour period.

Patients who do not respond to the prescribed dose of sumatriptan should not take a second dose for the same attack. Sumatriptan may be taken for subsequent attacks.
Sumatriptan is recommended as monotherapy for the acute treatment of migraine and should not be given concomitantly with other acute migraine therapies. If a patient fails to respond to a single dose of sumatriptan there are no reasons, either on theoretical grounds or from limited clinical experience, to withhold products containing aspirin or non-steroidal anti-inflammatory drugs for further treatment of the attack.

The tablets should be swallowed whole with water.

*Children (under 12 years of age)*
Sumatriptan tablets are not recommended for use in children below 12 as sumatriptan tablets have not been studied in children.

*Adolescents (12 to 17 years of age)*
The efficacy of sumatriptan tablets in adolescents could not be demonstrated in the clinical studies performed in this age group. Therefore the use in adolescents is not recommended (see section 5.1 Pharmacodynamic Properties).

*Elderly (Over 65 years of age)*
Experience of the use of sumatriptan in patients aged over 65 years is limited. The pharmacokinetics do not differ significantly from a younger population but until further clinical data are available, the use of sumatriptan in patients aged over 65 years is not recommended.

*Hepatic insufficiency*
Low doses of 25-50 mg should be considered for patients with mild to moderate liver impairment.

4.3 **Contraindications**

Hypersensitivity to the active substance, other sulphonamides or to any of the excipients.

Sumatriptan should not be given to patients who have had myocardial infarction or have ischaemic heart disease, coronary vasospasm (Prinzmetal’s angina), peripheral vascular disease or patients who have symptoms or signs consistent with ischaemic heart disease.

Sumatriptan should not be administered to patients with a history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA).

Sumatriptan should not be administered to patients with severe hepatic impairment.

The use of sumatriptan in patients with moderate and severe hypertension and mild uncontrolled hypertension is contraindicated.

The concomitant administration of ergotamine or derivatives of ergotamine (including methysergide) is contraindicated (See Section 4.5.).
Concurrent administration of monoamine oxidase inhibitors and sumatriptan is contraindicated.

Sumatriptan must not be used within two weeks of discontinuation of therapy with monoamine oxidase inhibitors.

4.4 Special warnings and precautions for use

Sumatriptan should only be used where there is a clear diagnosis of migraine.

Sumatriptan is not indicated for use in the management of hemiplegic, basilar or ophthalmoplegic migraine.

As with other migraine therapies, before treating headaches in patients not previously diagnosed as migraineurs, and in migraineurs who present atypical symptoms, care should be taken to exclude other potentially serious neurological conditions.

It should be noted that migraineurs may be at risk of certain cerebrovascular events (e.g. cerebrovascular accident, transient ischaemic attack).

Following administration, sumatriptan can be associated with transient symptoms including chest pain and tightness which may be intense and involve the throat (See Section 4.8.). Where such symptoms are thought to indicate ischaemic heart disease, no further doses of sumatriptan should be given and appropriate evaluation should be carried out.

Sumatriptan should not be given to patients with risk factors for ischaemic heart disease without prior cardiovascular evaluation (see section 4.3). Special consideration should be given to postmenopausal women and males over 40 with these risk factors. These evaluations however, may not identify every patient who has cardiac disease and, in very rare cases, serious cardiac events have occurred in patients without underlying cardiovascular disease.

Sumatriptan should be administered with caution to patients with controlled hypertension as transient increases in blood pressure and peripheral vascular resistance have been observed in a small proportion of patients.

There have been rare post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. Serotonin syndrome has also been reported following concomitant treatment with triptans and serotonin noradrenaline reuptake inhibitors (SNRIs).

If concomitant treatment with sumatriptan and SSRI/SNRI is clinically warranted, appropriate observation of the patient is advised (see Section 4.5).

Sumatriptan should be administered with caution to patients with conditions which may affect significantly the absorption, metabolism or excretion of drugs, e.g. impaired hepatic or renal function.

Sumatriptan should be used with caution in patients with a history of seizures or other risk factors which lower the seizure threshold, as seizures have been reported in association with sumatriptan (see section 4.8).
Patients with known hypersensitivity to sulphonamides may exhibit an allergic reaction following administration of sumatriptan. Reactions may range from cutaneous hypersensitivity to anaphylaxis. Evidence of cross-sensitivity is limited but caution should be exercised before using sumatriptan in these patients.

Prolonged use of any type of painkiller for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained and treatment should be discontinued. The diagnosis of medication overuse headache (MOH) should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of headache medications.

Undesirable effects may be more common during concomitant use of triptans and herbal preparations containing St John’s wort (Hypericum perforatum).

Lactose
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Studies in healthy subjects show that sumatriptan does not interact with propranolol, flunarizine, pizotifen or alcohol. Sumatriptan has the potential to interact with MAOIs, ergotamine and derivatives of ergotamine (see also Contraindications). The increased risk of coronary vasospasm is a theoretical possibility and concomitant administration is contra-indicated. (see section 4.3).

Prolonged vasospastic reactions have been reported with ergotamine. As these effects may be additive, 24 hours should elapse before sumatriptan can be taken following any ergotamine-containing preparation. Conversely, ergotamine-containing preparations should not be taken until 6 hours have elapsed following sumatriptan administration.

There have been rare post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of SSRIs and sumatriptan. Serotonin syndrome has also been reported following concomitant treatment with triptans and SNRIs (see Section 4.4).

There may be a risk of serotonergic syndrome also if sumatriptan is used concomitantly with lithium.

Rarely, an interaction may occur between sumatriptan and SSRIs (see Section 4.4.).

4.6 Pregnancy and lactation

Use during pregnancy
Post-marketing data from the use of sumatriptan during the first trimester in over 1,000 women are available. Although these data contain insufficient information to draw definitive conclusions, they do not point to an increased risk of congenital defects. Experience with the use of sumatriptan in the second and third trimester is limited. Evaluation of experimental animal studies does not indicate direct teratogenic effects or harmful effects on peri- and postnatal development. However, embryofoetal viability might be affected in the rabbit (see section 5.3).
Administration of sumatriptan should only be considered if the expected benefit to the mother is greater than any possible risk to the fœtus.

**Use during breast-feeding**
It has been demonstrated that following subcutaneous administration sumatriptan is secreted into breast milk. Infant exposure can be minimised by avoiding breast feeding for 12 hours after treatment.

### 4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. Account should be taken of the fact that symptoms such as dizziness and weakness caused by a migraine attack itself or by treatment with sumatriptan may affect ability to drive or operate machines.

### 4.8 Undesirable effects

Adverse events are listed below by system organ class and frequency. Frequencies are defined as:

- Very common (>1/10)
- Common (≥1/100 to <1/10)
- Uncommon (≥1/1,000 to <1/100)
- Rare (≥1/10,000 to <1/1,000)
- Very rare (<1/10,000), not known (cannot be estimated from the available data)

**Clinical Trial Data**

**Investigations**

*Very rare*: Minor disturbances in liver function tests have occasionally been observed.

**Nervous system disorders**

*Common*: Tingling, dizziness, drowsiness.

**Gastrointestinal**

*Common*: Nausea and vomiting occurred in some patients but it is unclear if this is related to sumatriptan or the underlying condition.

**Musculoskeletal and connective tissue disorders**

*Common*: Sensations of heaviness (usually transient and may be intense and can affect any part of the body including the chest and throat).

**Vascular disorders**

*Common*: Transient increases in blood pressure arising soon after treatment. Flushing.

**General disorders and administration site conditions**

*Common*: Pain, sensations of heat, pressure or tightness (these events are usually transient and may be intense and can affect any part of the body including the chest and throat).
*Uncommon:* Feelings of weakness, fatigue (both events are mostly mild to moderate in intensity and transient).

**Post-Marketing Data**

**Cardiac disorders**

*Very rare:* Bradycardia, tachycardia, palpitations, cardiac arrhythmias, transient ischaemic ECG changes, coronary artery vasospasm, myocardial infarction (see Contraindications, Warnings and Precautions).

**Nervous system disorders**

*Very rare:* Seizures, although some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures there are also reports in patients where no such predisposing factors are apparent. Tremor, dystonia.

**Eye disorders**

*Very rare:* Flickering, diplopia, reduced vision, nystagmus & scotoma. Loss of vision including reports of permanent defects. However, visual disorders may also occur during a migraine attack itself.

**Gastrointestinal**

*Very rare:* Ischaemic colitis

**Musculoskeletal, connective tissue and bone disorders**

*Very rare:* Neck stiffness.

**Vascular disorders**

*Very rare:* Hypotension, Raynaud's phenomenon.

**Immune system disorders**

*Very rare:* Hypersensitivity reactions ranging from cutaneous hypersensitivity to rare cases of anaphylaxis

**4.9 Overdose**

Patients have received up to 12 mg of sumatriptan, as a single subcutaneous injection without significant undesirable effects. With subcutaneous doses exceeding 16 mg and oral doses exceeding 400 mg, no other undesirable adverse effects have been observed than those mentioned in “section 4.8”.

In cases of overdose, the patient must be monitored for at least 10 hours and if necessary, standard supportive treatment must be given.

There is no information on the effect of hemodialysis or peritoneal dialysis on plasma sumatriptan concentrations.
PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

*Pharmacotherapeutic group:* Analgesics: antimigraine preparations: Selective serotonin (5HT1) agonist

ATC Code: N02C C01

Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine\(_1\) (5HT\(_{1D}\)) receptor agonist with no effect on other 5HT receptor (5-HT\(_2\)-5-HT\(_7\)) subtypes. The vascular 5-HT\(_{1D}\) receptor is found predominantly in cranial blood vessels and mediates vasoconstriction. In animals, sumatriptan selectively constricts the carotid arterial circulation but does not alter cerebral blood flow. The carotid arterial circulation supplies blood to the extracranial and intracranial tissues such as the meninges and dilatation of and/or oedema formation in these vessels is thought to be the underlying mechanism of migraine in man.

In addition, evidence from animal studies suggests that sumatriptan inhibits trigeminal nerve activity. Both these actions (cranial vasoconstriction and inhibition of trigeminal nerve activity) may contribute to the anti-migraine action of sumatriptan in humans.

Sumatriptan remains effective in treating menstrual migraine i.e. migraine without aura that occurs between 3 days prior and up to 5 days post onset of menstruation. Sumatriptan should be taken as soon as possible in an attack.

Clinical response begins around 30 minutes following a 100 mg oral dose.

Although the recommended dose of oral sumatriptan is 50 mg, migraine attacks vary in severity both within and between patients. Doses of 25 – 100 mg have shown greater efficacy than placebo in clinical trials, but 25 mg is statistically significantly less effective than 50 and 100 mg.

Five placebo-controlled clinical studies assessed the safety and efficacy of oral sumatriptan in approximately 600 adolescent migraineurs aged 12 – 17 years. These studies failed to demonstrate a statistically significant difference in headache relief at 2 hours between placebo and any sumatriptan dose. The undesirable effects profile of oral sumatriptan in adolescents aged 12 – 17 years was similar to that reported from studies in the adult population.

5.2 Pharmacokinetic properties

Following oral administration, sumatriptan is rapidly absorbed, 70 % of maximum concentration occurring at 45 minutes. After 100 mg dose, the maximum plasma concentration is 54 ng/ml. Mean absolute oral bioavailability is 14 % partly due to presystemic metabolism and partly due to incomplete absorption. The elimination phase half-life is approximately 2 hours, although there is an indication of a longer terminal phase. Plasma protein binding is low (14 – 21 %), mean volume of distribution is 170 litres. Mean total plasma clearance is approximately 1160 ml/min and the mean renal
plasma clearance is approximately 260 ml/min. Non-renal clearance accounts for about 80% of the total clearance. Sumatriptan is eliminated primarily by oxidative metabolism mediated by monoamine oxidase A. The major metabolite, the indole acetic acid analogue of sumatriptan is mainly excreted in the urine, where it is present as a free acid and the glucuronide conjugate. It has no known 5HT1 or 5HT2 activity. Minor metabolites have not been identified. The pharmacokinetics of oral sumatriptan do not appear to be significantly affected by migraine attacks.

In a pilot study, no significant differences were found in the pharmacokinetic parameters between the elderly and young healthy volunteers.

5.3 Preclinical safety data

Sumatriptan was devoid of genotoxic and carcinogenic activity in in-vitro systems and animal studies.

In a rat fertility study oral doses of sumatriptan resulting in plasma levels approximately 200 times those seen in man after a 100 mg oral dose were associated with a reduction in the success of insemination.

This effect did not occur during, a subcutaneous study where maximum plasma levels achieved approximately 150 times those in man by the oral route.

In rabbits embryolethality, without marked teratogenic defects, was seen. The relevance for humans of these findings is unknown.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Lactose monohydrate
Croscarmellose sodium
Microcrystalline cellulose
Anhydrous lactose
Magnesium stearate
Film coating
Lactose monohydrate
Mannitol (E421)
Titanium dioxide (E171)
Triacetin
Talc

6.2 Incompatibilities

Not applicable.
6.3 Shelf life
2 years.

6.4 Special precautions for storage
Do not store above 25º C.

6.5 Nature and contents of container
Aluminium foil/PVdC coated PVC blister strips of 2, 3, 4, or 6 tablets in cartons of 2, 3, 4, 6, 12
or 18 tablets.

6.6 Special precautions for disposal
No special requirements

7 MARKETING AUTHORISATION HOLDER
Dr. Reddy’s Laboratories (UK) Ltd.,
6 Riverview Rd,
Beverley,
HU17 0LD,
UK.

8 MARKETING AUTHORISATION NUMBER(S)
PL 08553/0226

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
14/05/2011

10 DATE OF REVISION OF THE TEXT
14/05/2011